
#### **Listing of Claims:**

The listing of the claims which follows replaces any and all prior versions and/or listings of the claims in the application.

- 1-4. (Canceled)
- 5-10. (Previously Canceled)
- 11-18. (Canceled)
- 19. (Currently Amended) The A compound according to Claim 18 represented by Formula Ia:



or a pharmaceutically acceptable salt or hydrate thereof, wherein

R<sup>10</sup> is selected from the group consisting of:

- (1) phenyl,
- (2) benzyl, and
- (3) HET, wherein HET is a 5-membered aromatic or non-aromatic monocyclic ring containing 1-3 heteroatoms selected from O, S and N,

wherein groups (1) to (3) above are optionally substituted with 1 to 3 substituents independently selected from the group consisting of:

- (a) halo,
- (b) C<sub>1-4</sub>alkyl, optionally substituted with hydroxy or 1 to 3 halo groups,
- (c) C<sub>1-4</sub>alkoxy, optionally substituted with 1 to 3 halo groups,
- (d) NH<sub>2</sub>,
- (e) hydroxy, and
- (e) phenyl or benzyl;[[.]]

n and m are each independently 0, 1 or 2;

## K is selected from NR<sup>3</sup> or $C(R^3)(R^4)$ ;

L is selected from NR5 or C(R5)(R6);

<u>X is a bond, -C(O), -N(R<sup>14</sup>)-, -N(R<sup>14</sup>)-C(O)-, -C(O)-N(R<sup>14</sup>)-, -N(R<sup>14</sup>)-S(O)<sub>k</sub>-, -N(R<sup>14</sup>)-C(O)-NH- or -S(O)<sub>k</sub>-N(R<sup>14</sup>);</u>

#### k is 0, 1 or 2;

- R<sup>1</sup> is selected from the group consisting of:
- (1) C<sub>1</sub>-6alkyl,
- (2) C<sub>2-6</sub>alkenyl,
- (3) C<sub>2</sub>-6akynyl,
- (4) C<sub>3-6</sub>cycloalkyl,
- (5) C<sub>1-6</sub>alkoxy,
- (6)  $C_1$ -6alkyl-S(O)<sub>k</sub>-, wherein k is 0, 1 or 2,
- (7) aryl,
- (8) aryl C<sub>1</sub>-6alkyl,
- (9) HET,
- (10) -C<sub>1</sub>-6alkyl-HET,
- (11) aryloxy,
- (12) aroyloxy,
- (13) aryl C<sub>2</sub>-6alkenyl,
- (14) aryl C<sub>2-6</sub>alkynyl,
- (15) hydrogen,
- (16) hydroxyl and
- (17) cyano

wherein items (1) to (6) above and the alkyl portions of items (8) and (10) above and the alkenyl portion of item (13) above and the alkynyl portion of item (14) above are optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, oxo,  $OR^{13}$ ,  $N(R^{14})_2$ ,  $C_{3-6}$ cycloalkyl and  $C_{1-6}$ alkyl- $S(O)_{k-}$ , wherein k is 0, 1 or 2, and

wherein the aryl is optionally substituted from one up to the maximum number of substitutable positions with halo; the aryl is items (7), (9), (11) and (12) above and aryl portion of items (8), (13) and (14) above and the HET portion of item (10) above are optionally substituted

from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of:

- (a) halo,
- (b)  $OR^{13}$ ,
- (c)  $N(R^{14})_{2}$
- (d) C<sub>1-6</sub>alkyl,
- (e) C2-6alkenyl,
- (f) C2-6akynyl,
- (g)  $C_{1-6}$ alkyl- $S(O)_{k-}$ , wherein k is 0, 1 or 2,
- (h) aryl,
- (i)  $aryl-S(O)_k$ -, wherein k is 0, 1 or 2,
- (i) HET,
- (k) aryl C<sub>1</sub>-6alkyl,
- (l) aroyl,
- (m) aryloxy,
- (n) aryl C<sub>1</sub>-6alkoxy,
- (o) CN and
- (p) C3-6cycloalkyl,

wherein items (d) to (g) and (p) above and the alkyl portions of item (k) above are optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, OR<sup>13</sup> and N(R<sup>14</sup>)<sub>2</sub>, and

wherein items (h), (i), (j), (l) and (m) above and the aryl portions of items (k) and (n) above are optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, OR<sup>13</sup> and C<sub>1</sub>-4alkyl,

- R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are each independently selected from the group consisting of:
- (1) hydrogen,
- (2) halo,
- (3) C<sub>1-6alkyl</sub>,
- (4) C<sub>2</sub>-6alkenyl,
- (5) <u>C2-6akynyl</u>,
- (6) C3-6cycloalkyl,
- (7) C<sub>1-6</sub>alkoxy,
- (8)  $C_1$ -6alkyl-S(O)<sub>k</sub>-, wherein k is 0, 1 or 2,
- (9) aryl,
- (10) aryl C<sub>1</sub>-6alkyl,
- (11) HET and

#### (12) -C<sub>1</sub>-6alkyl-HET,

wherein items (3) to (8) above and the alkyl portions of items (10) and (12) above are optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo,  $OR^{13}$ ,  $N(R^{14})_2$  and  $C_{1-6}$ alkyl- $S(O)_{k-}$ , wherein k is 0, 1 or 2; and

wherein items (9) and (11) and the aryl portion of items (10) and the HET portion of item (12) are optionally substituted from one up to the maximum number of substituable positions with a substituent independently selected from the group consisting of:

- (a) halo,
- (b)  $OR^{13}$ ,
- (c)  $N(R^{14})_{2}$
- (d) C<sub>1-6</sub>alkyl,
- (e) C2-6alkenyl,
- (f) C2-6akynyl and
- (g)  $C_{1-6}$ alkyl- $S(O)_{k-}$ , wherein k is 0, 1 or 2,

wherein items (d) to (g) above are optionally substituted with from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, OR13 and N(R14)2.

or R1 and R3 or R3 and R5 may be joined together to form a double bond;

R<sup>7</sup> is selected from the group consisting of:

- (1) hydrogen,
- (2)  $OR^{13}$ ,
- (3)  $C_1$ -4alkyl,
- (4) aryl and
- (5) aryl C<sub>1</sub>-4alkyl,

wherein item (3) above and the alkyl portion of item (5) above are optionally substituted with from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, OR 13 and N(R 14)2, and

wherein item (4) above and the aryl portion of item (5) above are optionally substituted with from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of:

- (a) halo,
- (b) OR 13,
- (c)  $N(R^{14})_2$ ,

- (d) C<sub>1</sub>-6alkyl,
- (e) C2-6alkenyl and
- (f) C2-6akynyl,

wherein items (d) to (f) above are optionally substituted with from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, OR13 and N(R14)2;

### Y<sub>1</sub> is selected from the group consisting of:

- (1) hydrogen,
- (2)  $-O-R^9$ ,
- (3)  $-S(O)_k-R^9$ , wherein k is 0, 1 or 2,
- (4) -C-W-R9, wherein W is O or S(O)k,
- (5) -N(R<sup>15</sup>)2,
- (6)  $-S(O)_k-N(R^{15})_{2}$
- (7) -N(R<sup>15</sup>)-S(O)k-N(R<sup>15</sup>)<sub>2</sub>,
- (8) NO<sub>2</sub>,
- (9) -C(O)-R15,
- (10) -C(O)O-R<sup>15</sup>,
- (11) -CN,
- (12) halo,
- (13)  $-O-S(O)_k-R^{15}$  and
- (14) C<sub>1</sub>-4alkyl, optionally substituted with from 1 to 6 halo groups,

#### <u>Y2 is CF3;</u>

 $R^9$  is selected from the group consisting of: hydrogen,  $C_{1-12}$ alkyl and aryl, wherein  $C_{1-12}$ alkyl and aryl are optionally substituted from one up to the maximum number of substituents with halo;

each R<sup>11</sup>, R<sup>12</sup> and R<sup>16</sup> is independently selected from the group consisting of:

- (1) hydrogen,
- (2) halo,
- (3) C<sub>1</sub>-6alkyl,
- (4) C<sub>2-6</sub>alkenyl,
- (5) C<sub>1</sub>-6alkoxy and
- (6) hydroxy,

wherein items (3) to (5) above are optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, OR12, N(R13)2 and C1-6alkyl-S(O)k-, wherein k is 0, 1 or 2,

each R<sup>13</sup> and R<sup>14</sup> is independently selected from the group consisting of hydrogen and C<sub>1-4</sub>alkyl, optionally substituted from one up to the maximum number of substitutable positions with halo; and

each R<sup>15</sup> is independently selected from the group consisting of: hydrogen, C<sub>1</sub>-6alkyl, aryl and C<sub>1-12</sub>alkoxycarbonyl, wherein said C<sub>1-6</sub>alkyl and C<sub>1-12</sub>alkoxycarbonyl are optionally substituted from one up to the maximum number of substituable positions with halo and said aryl is optionally substituted from one up to the maximum number of substituable positions with halo and C<sub>1-4</sub>alkyl, optionally substituted with 1-3 halo groups.

20. (Currently Amended) The A compound according to Claim 3 represented by Formula Ia:

$$R^{16}$$
 $R^{16}$ 
 $R^{7}$ 
 $R^{7}$ 
 $R^{7}$ 
 $R^{7}$ 
 $R^{10}$ 
 $R^{10}$ 
 $R^{11}$ 
 $R^{10}$ 
 $R^{11}$ 
 $R^{10}$ 

or a pharmaceutically acceptable salt or hydrate thereof, wherein

 $Y_2$  is hydrogen, X is a bond, and  $R^{10}$  is HET, wherein HET is a 5-membered aromatic or non-aromatic monocyclic ring containing 1-3 heteroatoms selected from O, S and  $N_{:}[[.]]$ 

n and m are each independently 0, 1 or 2;

K is selected from  $NR^3$  or  $C(R^3)(R^4)$ ;

L is selected from NR5 or C(R5)(R6);

R<sup>1</sup> is selected from the group consisting of:
(1) C<sub>1-6</sub>alkyl,

- (2) C2-6alkenyl,
- (3) C2-6akynyl,
- (4) C3-6cycloalkyl,
- (5) C<sub>1</sub>-6alkoxy,
- (6)  $C_{1-6}$ alkyl- $S(O)_{k-}$ , wherein k is 0, 1 or 2,
- (7) aryl,
- (8) aryl C<sub>1-6</sub>alkyl,
- (9) HET,
- (10) -C<sub>1</sub>-6alkyl-HET,
- (11) aryloxy,
- (12) aroyloxy,
- (13) aryl C<sub>2</sub>-6alkenyl,
- (14) aryl C<sub>2</sub>-6alkynyl,
- (15) hydrogen,
- (16) hydroxyl and
- (17) cyano

wherein items (1) to (6) above and the alkyl portions of items (8) and (10) above and the alkenyl portion of item (13) above and the alkynyl portion of item (14) above are optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, oxo,  $OR^{13}$ ,  $N(R^{14})_2$ ,  $C_{3-6}$ cycloalkyl and  $C_{1-6}$ alkyl- $S(O)_{k-}$ , wherein k is 0, 1 or 2, and

wherein the aryl is optionally substituted from one up to the maximum number of substitutable positions with halo; the aryl is items (7), (9), (11) and (12) above and aryl portion of items (8), (13) and (14) above and the HET portion of item (10) above are optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of:

- (a) halo,
- (b)  $OR^{13}$ ,
- (c)  $N(R^{14})_2$ ,
- (d) C<sub>1-6</sub>alkyl,
- (e) C2-6alkenyl,
- (f) C2-6akynyl,
- (g)  $C_1$ -6alkyl-S(O)<sub>k</sub>-, wherein k is 0, 1 or 2,
- (h) aryl,
- (i)  $aryl-S(O)_k$ , wherein k is 0, 1 or 2,
- (i) HET,

- (k) aryl C<sub>1</sub>-6alkyl,
- (l) aroyl,
- (m) aryloxy,
- (n) aryl C<sub>1-6</sub>alkoxy,
- (o) CN and
- (p) C3-6cycloalkyl,

wherein items (d) to (g) and (p) above and the alkyl portions of item (k) above are optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo,  $OR^{13}$  and  $N(R^{14})$ , and

wherein items (h), (i), (j), (l) and (m) above and the aryl portions of items (k) and (n) above are optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, OR<sup>13</sup> and C<sub>1</sub>-4alkyl,

- R3, R4, R5 and R6 are each independently selected from the group consisting of:
- (1) hydrogen,
- (2) halo,
- (3) C<sub>1-6</sub>alkyl,
- (4) C2-6alkenyl,
- (5) C<sub>2-6</sub>akynyl,
- (6) C3-6cycloalkyl,
- (7) C<sub>1-6</sub>alkoxy,
- (8)  $C_1$ -6alkyl- $S(O)_k$ -, wherein k is 0, 1 or 2,
- (9) arvl.
- (10) aryl C<sub>1</sub>-6alkyl,
- (11) HET and
- (12) -C<sub>1</sub>-6alkyl-HET,

wherein items (3) to (8) above and the alkyl portions of items (10) and (12) above are optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, OR<sup>13</sup>, N(R<sup>14</sup>)<sub>2</sub> and C<sub>1-6</sub>alkyl-S(O)<sub>k-</sub>, wherein k is 0, 1 or 2; and

wherein items (9) and (11) and the aryl portion of items (10) and the HET portion of item (12) are optionally substituted from one up to the maximum number of substituable positions with a substituent independently selected from the group consisting of:

- (a) halo,
- (b) OR 13,
- (c)  $N(R^{14})_2$ ,

- (d) C<sub>1-6</sub>alkyl,
- (e) C2-6alkenyl,
- (f) C2-6akynyl and
- (g)  $C_{1-6}$ alkyl- $S(O)_{k-}$ , wherein k is 0, 1 or 2,

wherein items (d) to (g) above are optionally substituted with from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, OR13 and N(R14)2.

or R<sup>1</sup> and R<sup>3</sup> or R<sup>3</sup> and R<sup>5</sup> may be joined together to form a double bond;

- R<sup>7</sup> is selected from the group consisting of:
- (1) hydrogen,
- (2)  $OR^{13}$ ,
- (3) C<sub>1-4alkyl</sub>,
- (4) aryl and
- (5) aryl C<sub>1</sub>-4alkyl,

wherein item (3) above and the alkyl portion of item (5) above are optionally substituted with from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, OR<sup>13</sup> and N(R<sup>14</sup>)2, and

wherein item (4) above and the aryl portion of item (5) above are optionally substituted with from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of:

- (a) halo,
- (b)  $OR^{13}$ ,
- (c)  $N(R^{14})_{2}$
- (d) C<sub>1-6</sub>alkyl,
- (e) C2-6alkenyl and
- (f) C2-6akynyl,

wherein items (d) to (f) above are optionally substituted with from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo, OR13 and N(R14)2;

Y<sub>1</sub> is selected from the group consisting of:

- (1) hydrogen,
- (2)  $-O-R^9$ ,
- (3) -S(O)<sub>k</sub>-R<sup>9</sup>, wherein k is 0, 1 or 2,
- (4) -C-W-R9, wherein W is O or S(O)k,

- (5) -N(R<sup>15</sup>)2,
- (6)  $-S(O)_k-N(R^{15})_{2}$
- (7) -N(R<sup>15</sup>)-S(O)k-N(R<sup>15</sup>)<sub>2</sub>,
- (8) NO<sub>2</sub>,
- (9)  $-C(O)-R^{15}$ ,
- (10) -C(O)O-R<sup>15</sup>,
- (11) -CN,
- (12) halo,
- (13) -O-S(O)<sub>k</sub>-R<sup>15</sup> and
- (14) C<sub>1</sub>-4alkyl, optionally substituted with from 1 to 6 halo groups,

R<sup>9</sup> is selected from the group consisting of: hydrogen, C<sub>1-12</sub>alkyl and aryl, wherein C<sub>1-12</sub>alkyl and aryl are optionally substituted from one up to the maximum number of substituents with halo;

each R11, R12 and R16 is independently selected from the group consisting of:

- (1) hydrogen,
- (2) halo,
- (3) C<sub>1-6</sub>alkyl,
- (4) C2-6alkenyl,
- (5) C<sub>1-6</sub>alkoxy and
- (6) hydroxy,

wherein items (3) to (5) above are optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo,  $OR^{12}$ ,  $N(R^{13})_2$  and  $C_{1-6}$ alkyl- $S(O)_{k-}$ , wherein k is 0, 1 or 2;

each R<sup>13</sup> and R<sup>14</sup> is independently selected from the group consisting of hydrogen and C<sub>1-4</sub>alkyl, optionally substituted from one up to the maximum number of substitutable positions with halo; and

each R<sup>15</sup> is independently selected from the group consisting of: hydrogen, C<sub>1</sub>-6alkyl, aryl and C<sub>1-12</sub>alkoxycarbonyl, wherein said C<sub>1-6</sub>alkyl and C<sub>1-12</sub>alkoxycarbonyl are optionally substituted from one up to the maximum number of substituable positions with halo and said aryl is optionally substituted from one up to the maximum number of substituable positions with halo and C<sub>1-4</sub>alkyl, optionally substituted with 1-3 halo groups.

21. (Original) The compound according to Claim 20 wherein HET is selected from oxazolyl and imidazolyl.

# 22. (Original) A compound selected from the group consisting of:

1	N, N O
2	F  CF3  HN  O  HN  O
3	F CF <sub>3</sub>
4	CF <sub>3</sub>
5	CF <sub>3</sub> HN O HN O

6	CF <sub>3</sub> HN O HN F
7	
8	CF <sub>3</sub>
9	CF <sub>3</sub> H H N H N H N H N H N H N H N H N H N
10	CF <sub>3</sub>
11	CF <sub>3</sub> HN CI

12	CF <sub>3</sub>
	N HN HN
	Br
	F
13	CF <sub>3</sub>
	HN
14	F CF <sub>3</sub>
17	
	N HN OFF
	<b>\</b>
15	CF <sub>3</sub>
	HN COFF
	r
16	Ţ F
16	CF <sub>3</sub>
	N HN F
	<u> </u>
17	F CF <sub>3</sub>
	N HN CI
	HN CI
	F

18	CF <sub>3</sub>
19	CF 3 0 H
20	CF <sub>3</sub> HN N
21	CF <sub>3</sub> HN NH <sub>2</sub>
22	CF <sub>3</sub> HN O HN O
23	CF <sub>3</sub> HN O F

24	CF <sub>3</sub> HN O F F F F F F F F F F F F F F F F F F
25	CF <sub>3</sub> N H H F
26	CF <sub>3</sub> HN F
27	CF <sub>3</sub> HN CI
28	CF <sub>3</sub> HN O
29	CF <sub>3</sub>

30	CF <sub>3</sub> HN OH
31	CF <sub>3</sub> HN OH
32	CF <sub>3</sub> HN O
33	CF <sub>3</sub> HN CI
34	CF <sub>3</sub> HN F
35	CF <sub>3</sub> HN OH

36	CE S O HZ
37	CF <sub>3</sub> HN  F  F
38	CF <sub>3</sub> HN O F F F
39	CF <sub>3</sub> HN OH
40	CF <sub>3</sub>
41	CF <sub>3</sub>

42	CF <sub>3</sub>
	F
43	CF <sub>3</sub>
	F
44	CF <sub>3</sub> H N
	F
45	CF <sub>3</sub>
	F
46	CF <sub>3</sub>
	F

47	CF <sub>3</sub>
	<b>,</b>   <u>H</u>
	NN H
	N V
	F
48	CF <sub>3</sub>
	DH H
	N, N
10	F
49	CF <sub>3</sub>
	H H
	N N N
50	F CF <sub>3</sub>
	∎ [H H
	N N N
	N N
	F
51	CF <sub>3</sub>
	H H
	/ F

52	ÇF <sub>3</sub>
32	· · · · · · · · · · · · · · · · · · ·
	, , , , O
	N
	N N
	ŕ
53	CF <sub>3</sub>
	// / / // // / / / / / / / / / / / / /
	N, N
54	F F
34	
	CF <sub>3</sub> H
	N N N N N N N N N N N N N N N N N N N
	· N
	/ F
55	CF <sub>3</sub>
	H H
	N. J. J. T.
	N. ~~
	É F
56	$\downarrow$
	F 0
	F O CF <sub>3</sub>
	H H N
	N, J
	N V
	F

57	
58	CF <sub>3</sub>
	H N F
59	CF <sub>3</sub> H F
60	CF <sub>3</sub> H N OH
61	CF <sub>3</sub> NH <sub>2</sub> NH <sub>2</sub>

62	CF <sub>3</sub>
	F
63	CF <sub>3</sub>
64	CF <sub>3</sub>
65	CF <sub>3</sub>
66	CF <sub>3</sub> N  CF <sub>3</sub> CF <sub>3</sub>
67	CF <sub>3</sub>

(0)	CF.
68	CF <sub>3</sub>
	N = ''NH
	N O
	/ F
69	CF <sub>3</sub>
	NH H
	$N_{N}$
	F
70	CF <sub>3</sub>
	NH NH
	N'N I
	F
71	CF <sub>3</sub>
	N N N N N N N N N N N N N N N N N N N
	N, I
	F
	/ F
72	CF <sub>3</sub>
	N/NH
	N, F
	/ F
73	CF <sub>3</sub>
	NH H
	N, III
	/ F

74	N CEN
	F
75	CF <sub>3</sub> NH OF S SO
76	CF <sub>3</sub>
77	CF <sub>3</sub> NH  O=S=O
78	CF <sub>3</sub>
79	CF <sub>3</sub> N  N  N  H  N  N  H  F

80	CF <sub>3</sub>
	NH F
	N O N H
81	F CF <sub>3</sub>
	NH NH
	N O N H
82	F CO <sub>2</sub> Me
	<b>T</b> [ ]
	N CO <sub>2</sub> Me
	N N
83	FCO <sub>2</sub> Me
	<b>,</b> [ ]
	N H CO <sub>2</sub> Me
	N N
84	F΄ ,,,,,CO₂Me
07	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
	N CO <sub>2</sub> Me
	N T
	F F

C-	20.14
85	CO <sub>2</sub> Me
	N CO <sub>2</sub> Me
	N 11
0.6	F CO Ma
86	CO <sub>2</sub> Me
	N CO <sub>2</sub> Me
	N T
87	É .
67	CF <sub>3</sub> CO <sub>2</sub> Me
	N CO <sub>2</sub> Me
	N
	F
88	
	CF <sub>3</sub>
	NN CO <sub>2</sub> Me
	F
89	■ NCF3
	$CF_3$ $CO_2Me$
	N H SS <sub>2</sub> IIIS
	ŕ

90	05
	CF <sub>3</sub>
	N H CO <sub>2</sub> IVIE
	F
91	
	N CO <sub>2</sub> Me
	N <sub>N</sub> 11
92	F <sup>'</sup>
	H"CO <sub>2</sub> Me
	N V
	F
93	CO <sub>2</sub> Me
	mCF <sub>3</sub>
	N HCO <sub>2</sub> Me
0.4	F CO Ma
94	CF <sub>3</sub>
	N HCO <sub>2</sub> Me
	N 11 2
	F

95	N N H Y O
	F
96	N H O
97	F CO <sub>2</sub> Me
98	N CO <sub>2</sub> Me
99	N N Ph

100  101  102  103  CO <sub>2</sub> Me	100	^
101    N	100	_
101    N		······································
101  102  103  CO <sub>2</sub> Me		$N' \parallel V' \parallel V' \parallel V' \parallel V \parallel V \parallel V \parallel V \parallel V \parallel V$
102  R N N N N N N N N N N N N N CO <sub>2</sub> Me		N h
102  R N N N N N N N N N N N N N CO <sub>2</sub> Me		
102  R N N N N N N N N N N N N N CO <sub>2</sub> Me		
102  The state of		
102  R N N N N N N N N N N N N N CO <sub>2</sub> Me		/ F
102  R N N N N N N N N N N N N N CO <sub>2</sub> Me	101	
102  N  H  N  H  N  H  N  CO <sub>2</sub> Me		l H H
102  N  N  N  N  N  N  N  CO <sub>2</sub> Me		
102  N N N N N N CO <sub>2</sub> Me		N N N
102  N  N  CO <sub>2</sub> Me		
102  N  N  N  CO <sub>2</sub> Me		
102  N  N  CO <sub>2</sub> Me		
102  N  N  N  CO <sub>2</sub> Me		
103  H N N CO <sub>2</sub> Me	102	F
103	102	. Г н
103 CO <sub>2</sub> Me		N N
F CO <sub>2</sub> Me		N
F CO <sub>2</sub> Me		N V
103 CO <sub>2</sub> Me		
103 F CO <sub>2</sub> Me		
103 F CO <sub>2</sub> Me		
103 CO <sub>2</sub> IVIE	102	F CO Ma
	103	CO <sub>2</sub> ivie
CF <sub>3</sub>		∴"CF <sub>3</sub>
N HCO <sub>2</sub> Me		N <sup>"</sup>
N V		$N$ $\sim$
H		H
		f f

104	CF <sub>3</sub> CO <sub>2</sub> Me
	CO <sub>2</sub> ivie
	N <sub>N</sub> H CO <sub>2</sub> Me
	N H
105	FÉ CF₃
103	_ [
	N H CO <sub>2</sub> Me
	N H
106	CF <sub>3</sub>
	N, HN HN
107	CF <sub>3</sub>
	HN
	CF <sub>3</sub>
100	I F
108	CF <sub>3</sub>
	N HN CF3
	CF <sub>3</sub>
	Ė

109	CF <sub>3</sub>
	N HHN O
110	CF <sub>3</sub>
	N H HN
	F
111	CF <sub>3</sub>
	N H HN
	CI
112	É CF <sub>3</sub>
	N HN O
113	CF <sub>3</sub>
	CF <sub>3</sub>
	F
114	CF <sub>3</sub>
	N H N O F
	F

115	rCF₃
	N, H, N, O, CI
116	CF <sub>3</sub>
	NN THE NO
	F F
117	CF <sub>3</sub>
	NN H N N
118	CF <sub>3</sub>
	N, NH
	o F
119	F CF <sub>3</sub>
	NH NH
	N O
120	CF <sub>3</sub>
	N NH
	F

121	CF <sub>3</sub>
	NH '
	NN O
122	CF <sub>3</sub>
	NH NH
	F
123	CF <sub>3</sub>
	NH NH
	N O N
124	F CF <sub>3</sub>
12.	νή Ηνή
	N S
125	CF <sub>3</sub>
	NH NH
106	F
126	CF <sub>3</sub>
	NH NH
	É

	05
127	CF <sub>3</sub>
128	CF <sub>3</sub>
129	CF <sub>3</sub>
130	CF <sub>3</sub>
131	CF <sub>3</sub>
132	CF <sub>3</sub>

122	CF <sub>3</sub>
133	— H // // // // // // // // // // // // /
	// Y Y Y /NH
	N'N
	√ F
134	CF <sub>3</sub>
	MH MH MH
	N N
	F
135	CF <sub>3</sub>
	NH H
	N, N
	F
136	CF <sub>3</sub>
	NH NH
	N, I
	F
137	CF <sub>3</sub>
	NNH H
	N,
	F
138	CF <sub>3</sub>
	νή μ. "ŃΗ
	H V V O N
	<i>F</i>
•	<u> </u>

- 23. (Original) A pharmaceutical composition comprising a compound according to Claim 1 in combination with a pharmaceutically acceptable carrier.
- 24. (Withdrawn) A method for treating a glucocorticoid receptor mediated disease or condition in a mammalian patient in need of such treatment comprising administering the patient a compound according to Claim 1 in an amount that is effective for treating the glucocorticoid receptor mediated disease or condition.
  - 25-28. (Previously Canceled)
  - 29. (Original) A compound according to Claim 1 of Formula Id

or a pharmaceutically acceptable salt thereof, wherein

 $R^{10}$  is a 5-membered aromatic or non-aromatic mono-cyclic ring containing 1-3 heteroatoms selected from O, S, and N, and

 $R^{10}$  is mono-substituted with phenyl, wherein phenyl is optionally substituted with 1-3 substituents independently selected from halo,  $C_{1-4}$ alkyl and  $C_{1-4}$ alkoxy.

30. (Original) The compound according to Claim 29 wherein  $R^{10}$  is oxazolyl, oxadiazolyl or thiazolyl.

31. (Canceled)